The list includes 52 branded drugs from more than 30 different drugmakers, including Novartis, GlaxoSmithKline and Gilead Sciences. The agency believes these drug companies may be blocking generic drugmakers’ access to the branded drug samples they need to bring their own cheaper versions to the market.
“No patients should be priced out of medicines they need to support their health,” said FDA Commissioner Scott Gottlieb, MD. “We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval.”
The FDA published the list as part of its Drug Competition Action Plan, which the agency rolled out last spring.
More articles on supply chain:
Vermont first state to legalize drug importation from Canada
Janssen, Pharmacyclics cancel plan to triple cost of cancer drug after backlash
6 key proposals unveiled in Trump’s plan to combat rising drug costs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.